Malignancies in systemic lupus erythematosus

Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, characterized by a wide array of symptoms and organ involvements, leading to varying disease courses and outcome, and ranging from mild to severe types. In patients with SLE, the incidence and risk of malignancy develo...

Full description

Saved in:
Bibliographic Details
Main Authors: Kiss Emese
Kovács László
Szodoray Péter
Format: Article
Published: 2010
Series:AUTOIMMUNITY REVIEWS 9 No. 4
doi:10.1016/j.autrev.2009.07.004

mtmt:1911090
Online Access:http://publicatio.bibl.u-szeged.hu/15970
Description
Summary:Systemic lupus erythematosus (SLE) is a prototypical systemic autoimmune disease, characterized by a wide array of symptoms and organ involvements, leading to varying disease courses and outcome, and ranging from mild to severe types. In patients with SLE, the incidence and risk of malignancy development is increased, and mostly non-Hodgkin's lymphoma (NHL), cervical cancer, as well as bronchial carcinomas occur. Besides others, the common genetic predisposition, chronic antigen stimulus, disproportional immune responses, as well as the chronic administration of immunosuppressive medications can contribute to the development of malignancies in lupus. In this review we present the molecular pathology, as well as the epidemiological and clinical aspects of malignancies in patients with SLE.
Physical Description:195-199
ISSN:1568-9972